Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/9/2018
SIETES contiene 92557 citas

 
 
 1 a 20 de 55 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, García-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018:26 de agosto. [Ref.ID 102827]
2. Cita con resumen
O'Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Cannon CP, Serruys PW, for the SOLID-TIMI 52 Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome.The SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006-15. [Ref.ID 97951]
3.Tiene citas relacionadas Cita con resumen
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, for the CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92. [Ref.ID 96671]
4.Tiene citas relacionadas
Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran DJ, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzylio W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 2013;382:605-13. [Ref.ID 96025]
5. Cita con resumen
Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KAA, Breithardt G, Hacke W. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013;158:861-8. [Ref.ID 95680]
6.Tiene citas relacionadas Cita con resumen
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg G, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA, for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13. [Ref.ID 95246]
7.Tiene citas relacionadas Cita con resumen
Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, Zhou C, Jakubowski JA, White HD, Fox KAA, Prabhakaran D, Armstrong PW, Tantry US, Roe MT, for the TRILOGY ACS Platelet Function Substudy Investigators. Platelet function extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS Platelet Function Substudy. JAMA 2012;308:1785-94. [Ref.ID 94020]
8.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LHK, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW, for the TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20-33. [Ref.ID 92104]
9.Tiene citas relacionadas Cita con resumen
Mehta S, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht H-J, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand J-P, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KAA, Yusuf S, on behalf of the CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in invididuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233-43. [Ref.ID 89553]
10.Tiene citas relacionadas Cita con resumen
Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack Jr CV, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, for the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-41. [Ref.ID 87367]
11.Tiene citas relacionadas Cita con resumen
Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack Jr CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29. [Ref.ID 87366]
12.
Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, Collet JP, Steinhubl SR, Montalescot G. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention. Quantitative review of randomized trials. Arch Intern Med 2007;167:2423-30. [Ref.ID 81885]
13.
Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ, for the ACUITY Investigators. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management. One-year results from the ACUITY trial. JAMA 2007;298:2497-506. [Ref.ID 81745]
14.
Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, for the Acute Ctheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-19. [Ref.ID 79519]
15.Tiene citas relacionadas Cita con resumen
Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD, for the ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. The ACUITY Timing Trial. JAMA 2007;297:591-602. [Ref.ID 79318]
16.Tiene citas relacionadas
White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Results from SPORTIF III and V. Arch Intern Med 2007;167:239-45. [Ref.ID 79193]
17.Tiene citas relacionadas
Montalescot G, White HD, Steinhubl SR. Enoxaparin in elective percutaneous coronary intervention. The authors reply. N Engl J Med 2006;355:2790-1. [Ref.ID 78817]
18. Cita con resumen
Montalescot G, White HD, Gallo R, Steg PG, Aylward PEG, Bode C, Chiariello M, King III SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR, for the STEEPLE Investigators. Enoxaparin versus unfractionated heparin ni elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17. [Ref.ID 78033]
19.Tiene citas relacionadas Cita con resumen
Wong CK, Gao W, Raffel OC, French JK, Stewart RA, White HD, for the HERO-2 Investigators. Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2. Lancet 2006;367:2061-7. [Ref.ID 77310]
20.Tiene citas relacionadas
Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KAA, Braunwald E, for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-88. [Ref.ID 76659]
Seleccionar todas
 
 1 a 20 de 55 siguiente >>